Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.59 CHF 7.75% Market Closed
Market Cap: 185.3m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Molecular Partners AG
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Molecular Partners AG
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Molecular Partners AG
SIX:MOLN
Cash from Operating Activities
-CHf62m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Cash from Operating Activities
-$118.7m
CAGR 3-Years
11%
CAGR 5-Years
0%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cash from Operating Activities
CHf43.7m
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cash from Operating Activities
-$188.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Cash from Operating Activities
CHf10.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Cash from Operating Activities
-CHf2.4m
CAGR 3-Years
20%
CAGR 5-Years
28%
CAGR 10-Years
N/A
No Stocks Found

Molecular Partners AG
Glance View

Market Cap
185.3m CHF
Industry
Biotechnology

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

MOLN Intrinsic Value
2.91 CHF
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Molecular Partners AG's Cash from Operating Activities?
Cash from Operating Activities
-62m CHF

Based on the financial report for Jun 30, 2024, Molecular Partners AG's Cash from Operating Activities amounts to -62m CHF.

What is Molecular Partners AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-5%

Over the last year, the Cash from Operating Activities growth was 0%. The average annual Cash from Operating Activities growth rates for Molecular Partners AG have been -5% over the past three years .

Back to Top